The FDA has approved COVID-19 vaccines targeting strains related to the JN.1 variant for individuals 65 and older and those who have underlying conditions that put them at higher risk. For these higher-risk individuals, Moderna's mNEXSPIKE and Novavax's Nuvaxovid are approved for people who are 12 years and older, Moderna's SPIKEVAX is approved for people 6 months and older, and Pfizer's COMIRNATY is approved for people 5 years and older. mNEXSPIKE, SPIKEVAX, and COMIRNATY utilize mRNA technology while Nuvaxovid is protein-based. People over 6 months who don't fall into the high-risk category can still get the vaccines, with the approval of a doctor.
The FDA must complete its lot review process to release the vaccine for distribution, which may take a few days to weeks; however, vaccine supply should start arriving soon based on pharmacies' preorders.
Pharmacists' authority to order and administer COVID vaccines is determined by their state. Many states tie that authority to an ACIP recommendation. ACIP has not yet met to offer recommendations based upon the FDA's approval and we are waiting to hear when a meeting will be scheduled. If your state authority to vaccinate is tied to an ACIP recommendation, please wait to begin administering COVID vaccines unless your state allows it with a prescription for the vaccine from an authorized prescriber. Check with your state pharmacy association or board of pharmacy for information specific to your state.
NCPA is working closely with other professional pharmacy associations to advocate for solutions that ensure patients have access to COVID vaccines this fall.
